Initial drug susceptibility profile of M. tuberculosis among patients under TB programme in South India

International Journal of Tuberculosis and Lung Disease

Volumn 10, Issue 1, 2006, Pages 52-57

  Santha, T ^a   Thomas, A ^a   Chandrasekaran, V ^a   Selvakumar, N ^a   Gopi, P G ^a   Subramani, R ^a   Rajeswari, R ^a   Rani, B ^a   Paramasivan, C N ^a   Perumal, M ^b   Wares, F ^c   Narayanan, P R ^a  

^a NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^b Directorate of Medical Services   (India)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

DOTS; Drug susceptibility; Pulmonary tuberculosis; South India

Indexed keywords

ISONIAZID; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; DRUG SENSITIVITY; HEALTH PROGRAM; HUMAN; INDIA; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; SHORT COURSE THERAPY; SPUTUM SMEAR; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; STREPTOMYCIN; TUBERCULOSIS, PULMONARY;

EID: 33144476798     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. World Health Organization. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance: Anti-tuberculosis drug resistance in the world. Report No. 1. WHO/TB/97.229. Geneva, Switzerland: WHO 1997.
2. Paramasivan C N, Bhaskaran K, Venkataraman P, et al. Surveillance of drug resistance in tuberculosis in the state of Tamilnadu. Indian J Tuberc 2000; 47: 27-33.
3. World Health Organization. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance: Anti-tuberculosis drug resistance in the world. Report No. 2. Prevalence and trends. WHO/CDS/TB/2000.275. Geneva, Switzerland: WHO, 2000.
4. World Health Organization. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. Report 3. WHO/HTM/TB/2004.343. Geneva, Switzerland: WHO, 2004.
5. Malhotra B, Pathak S, Vyas L, et al. Drug susceptibility profile of M. tuberculosis isolates at Jaipur. Indian J Med Micobiol 2002; 20: 76-78.
6. Gupta P R, Singhal B, Sharma T N, Gupta R B. Prevalence of initial drug resistance in tuberculosis patients attending a chest hospital. Indian J Med Res 1993; 97: 219-224.
7. Ministry of Health and Family Welfare. RNTCP performance report. India: First Quarter 2005. New Delhi, India: Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India. www. tbcindia.org. Accessed June 2005.
8. Revised National Tuberculosis Control Programme technical guidelines for TB control. New Delhi, India: Central TB Division, Directorate General of Health Services, 1997.
9. Selvakumar N, Kumar V, Gopi P G, et al. Isolation of tubercle bacilli from sputum samples of patients in the field studies by the cetylpyridinium chloride-Sodium chloride and sodium hydroxide methods. Indian J Med Res 1995; 102: 149-151.
10. Allen B, Baker F J. Mycobacteria: isolation, identification and sensitivity testing. London, UK: Butterworth, 1968.
11. Canetti G, Fox W, Khomenko A, et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 1969; 41: 21-43.
12. Paramasivan C N, Rahman F, Nalini S, et al. Comparison of different methods of assessing in vitro resistance of M. tuberculosis to rifampicin. Indian J Med Res 2000; 114: 187-191.
13. Tuberculosis Research Centre, Madras. Study of chemotherapy regimens of 5 and 7 months' duration and the role of corticosteroids in the treatment of sputum positive patients with pulmonary tuberculosis in south India. Tubercle 1983; 64: 73-91.
14. World Health Organization. Revised international definitions in tuberculosis control. Int J Tuberc Lung Dis 2001; 5: 213-215.
15. Vijay S, Balasangameswara V H, Jagannatha P S, Kumar P. Initial drug resistance among tuberculosis patients under DOTS programme in Bangalore city. Indian J Tuberc 2004; 51: 17-21.
16. Vijay S, Balasangameswara V H, Jagannatha P S, et al. Re-treatment outcome of smear positive tuberculosis cases under DOTS in Bangalore city. Indian J Tuberc 2002; 49: 195-204.
17. Paramasivan C N, Chandrasekhar V, Santha T, et al. Bacteriological investigations for short course chemotherapy under the tuberculosis programme in 2 districts of India. Tubercle Lung Dis 1993; 74: 23-27.
18. Chandrasekharan S, Jagota P, Chaudhury K. Initial drug resistance to anti-tuberculosis drugs in urban and rural district tuberculosis programme. Indian J Tuberc 1992; 39: 171-176
19. Tuberculosis Research Centre, Madras. Low rate of emergence of drug resistant in sputum positive patients treated with short course chemotherapy. Int J Tuberc Lung Dis 2001; 5: 40-45.